Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
307.3 GBX | +5.96% | +11.33% | +8.58% |
04-26 | EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug | MT |
04-26 | Hutchmed notes CHMP's positive opinion for fruiquintinib approval | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+8.58% | 3.08B | |
+25.83% | 661B | |
+26.60% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+14.58% | 231B | |
+5.38% | 200B | |
-8.92% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- HCM Stock
- News HUTCHMED (China) Limited
- HUTCHMED (China) Initiates Bridging Study of Tazemetostat in Relapsed or Refractory Follicular Lymphoma Patients in China